Annual CFO
$389.90 M
+$50.50 M+14.88%
31 December 2023
Summary:
Neurocrine Biosciences annual cash flow from operations is currently $389.90 million, with the most recent change of +$50.50 million (+14.88%) on 31 December 2023. During the last 3 years, it has risen by +$161.40 million (+70.63%). NBIX annual CFO is now at all-time high.NBIX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$158.00 M
+$93.40 M+144.58%
30 September 2024
Summary:
Neurocrine Biosciences quarterly cash flow from operations is currently $158.00 million, with the most recent change of +$93.40 million (+144.58%) on 30 September 2024. Over the past year, it has dropped by -$54.00 million (-25.47%). NBIX quarterly CFO is now -25.47% below its all-time high of $212.00 million, reached on 30 September 2023.NBIX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
$476.40 M
-$54.00 M-10.18%
30 September 2024
Summary:
Neurocrine Biosciences TTM cash flow from operations is currently $476.40 million, with the most recent change of -$54.00 million (-10.18%) on 30 September 2024. Over the past year, it has increased by +$67.00 million (+16.37%). NBIX TTM CFO is now -26.19% below its all-time high of $645.40 million, reached on 31 March 2024.NBIX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +14.9% | -25.5% | +16.4% |
| 3 y3 years | +70.6% | +155.7% | +37.4% |
| 5 y5 years | +284.5% | +61.5% | +376.4% |
NBIX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +70.6% | -25.5% | +226.2% | -26.2% | +270.2% |
| 5 y | 5 years | at high | +284.5% | -25.5% | +226.2% | -26.2% | +376.4% |
| alltime | all time | at high | +467.2% | -25.5% | +226.2% | -26.2% | +353.1% |
Neurocrine Biosciences Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $158.00 M(+144.6%) | $476.40 M(-10.2%) |
| June 2024 | - | $64.60 M(-50.4%) | $530.40 M(-17.8%) |
| Mar 2024 | - | $130.30 M(+5.5%) | $645.40 M(+65.5%) |
| Dec 2023 | $389.90 M(+14.9%) | $123.50 M(-41.7%) | $389.90 M(-4.8%) |
| Sept 2023 | - | $212.00 M(+18.0%) | $409.40 M(+38.2%) |
| June 2023 | - | $179.60 M(-243.5%) | $296.20 M(+16.3%) |
| Mar 2023 | - | -$125.20 M(-187.6%) | $254.70 M(-25.0%) |
| Dec 2022 | $339.40 M(+32.3%) | $143.00 M(+44.7%) | $339.40 M(+69.2%) |
| Sept 2022 | - | $98.80 M(-28.5%) | $200.60 M(+22.6%) |
| June 2022 | - | $138.10 M(-441.0%) | $163.60 M(+27.1%) |
| Mar 2022 | - | -$40.50 M(-1064.3%) | $128.70 M(-49.8%) |
| Dec 2021 | $256.50 M(+12.3%) | $4.20 M(-93.2%) | $256.50 M(-26.0%) |
| Sept 2021 | - | $61.80 M(-40.1%) | $346.80 M(+31.1%) |
| June 2021 | - | $103.20 M(+18.2%) | $264.60 M(-5.6%) |
| Mar 2021 | - | $87.30 M(-7.6%) | $280.30 M(+22.7%) |
| Dec 2020 | $228.50 M(+55.4%) | $94.50 M(-563.2%) | $228.50 M(-1.3%) |
| Sept 2020 | - | -$20.40 M(-117.2%) | $231.50 M(-33.8%) |
| June 2020 | - | $118.90 M(+234.9%) | $349.70 M(+18.5%) |
| Mar 2020 | - | $35.50 M(-63.6%) | $295.00 M(+100.7%) |
| Dec 2019 | $147.00 M(+45.0%) | $97.50 M(-0.3%) | $147.00 M(+47.0%) |
| Sept 2019 | - | $97.80 M(+52.3%) | $99.99 M(+40.6%) |
| June 2019 | - | $64.20 M(-157.1%) | $71.11 M(+159.6%) |
| Mar 2019 | - | -$112.50 M(-322.8%) | $27.39 M(-73.0%) |
| Dec 2018 | $101.40 M(-207.5%) | $50.49 M(-26.7%) | $101.40 M(+10.8%) |
| Sept 2018 | - | $68.92 M(+236.5%) | $91.48 M(+590.0%) |
| June 2018 | - | $20.48 M(-153.2%) | $13.26 M(-123.9%) |
| Mar 2018 | - | -$38.49 M(-194.9%) | -$55.46 M(-41.2%) |
| Dec 2017 | -$94.33 M(-11.2%) | $40.58 M(-535.8%) | -$94.33 M(-43.4%) |
| Sept 2017 | - | -$9.31 M(-80.7%) | -$166.53 M(-11.5%) |
| June 2017 | - | -$48.24 M(-37.6%) | -$188.23 M(+22.0%) |
| Mar 2017 | - | -$77.36 M(+144.6%) | -$154.33 M(+45.3%) |
| Dec 2016 | -$106.18 M(+179.4%) | -$31.63 M(+2.0%) | -$106.18 M(+18.3%) |
| Sept 2016 | - | -$31.01 M(+116.3%) | -$89.76 M(+16.1%) |
| June 2016 | - | -$14.34 M(-50.9%) | -$77.32 M(+57.7%) |
| Mar 2016 | - | -$29.21 M(+92.1%) | -$49.02 M(+29.0%) |
| Dec 2015 | -$38.00 M(-19.4%) | -$15.20 M(-18.1%) | -$38.00 M(-0.3%) |
| Sept 2015 | - | -$18.57 M(-233.0%) | -$38.10 M(+20.5%) |
| June 2015 | - | $13.96 M(-176.8%) | -$31.63 M(-43.1%) |
| Mar 2015 | - | -$18.18 M(+18.8%) | -$55.56 M(+17.9%) |
| Dec 2014 | -$47.14 M(+59.2%) | -$15.31 M(+26.5%) | -$47.14 M(+10.4%) |
| Sept 2014 | - | -$12.10 M(+21.4%) | -$42.71 M(+3.2%) |
| June 2014 | - | -$9.96 M(+2.0%) | -$41.39 M(+0.3%) |
| Mar 2014 | - | -$9.77 M(-10.2%) | -$41.29 M(+39.4%) |
| Dec 2013 | -$29.61 M(-16.1%) | -$10.88 M(+0.9%) | -$29.61 M(+7.1%) |
| Sept 2013 | - | -$10.78 M(+9.3%) | -$27.64 M(+9.8%) |
| June 2013 | - | -$9.86 M(-615.7%) | -$25.16 M(+13.4%) |
| Mar 2013 | - | $1.91 M(-121.5%) | -$22.18 M(-37.2%) |
| Dec 2012 | -$35.29 M(+4956.4%) | -$8.91 M(+7.3%) | -$35.29 M(+129.7%) |
| Sept 2012 | - | -$8.30 M(+20.7%) | -$15.37 M(+258.2%) |
| June 2012 | - | -$6.88 M(-38.6%) | -$4.29 M(+29.1%) |
| Mar 2012 | - | -$11.20 M(-201.7%) | -$3.32 M(+375.9%) |
| Dec 2011 | -$698.00 K(-101.4%) | $11.02 M(+297.5%) | -$698.00 K(-95.7%) |
| Sept 2011 | - | $2.77 M(-146.9%) | -$16.25 M(-9.1%) |
| June 2011 | - | -$5.91 M(-31.1%) | -$17.88 M(-133.4%) |
| Mar 2011 | - | -$8.58 M(+89.5%) | $53.55 M(+7.2%) |
| Dec 2010 | $49.94 M | -$4.53 M(-496.8%) | $49.94 M(+23.3%) |
| Sept 2010 | - | $1.14 M(-98.3%) | $40.50 M(+43.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | $65.52 M(-637.6%) | $28.26 M(-155.5%) |
| Mar 2010 | - | -$12.19 M(-12.8%) | -$50.89 M(-4.1%) |
| Dec 2009 | -$53.09 M(-28.4%) | -$13.97 M(+25.9%) | -$53.09 M(-4.2%) |
| Sept 2009 | - | -$11.10 M(-18.6%) | -$55.41 M(-6.1%) |
| June 2009 | - | -$13.63 M(-5.3%) | -$59.01 M(-2.3%) |
| Mar 2009 | - | -$14.39 M(-11.7%) | -$60.39 M(-18.6%) |
| Dec 2008 | -$74.17 M(+25.0%) | -$16.29 M(+10.9%) | -$74.17 M(+19.4%) |
| Sept 2008 | - | -$14.70 M(-2.1%) | -$62.10 M(-9.9%) |
| June 2008 | - | -$15.01 M(-46.7%) | -$68.91 M(-5.2%) |
| Mar 2008 | - | -$28.17 M(+566.5%) | -$72.65 M(+22.4%) |
| Dec 2007 | -$59.33 M(-40.3%) | -$4.23 M(-80.3%) | -$59.33 M(-17.5%) |
| Sept 2007 | - | -$21.50 M(+14.6%) | -$71.91 M(-14.5%) |
| June 2007 | - | -$18.75 M(+26.3%) | -$84.15 M(-10.3%) |
| Mar 2007 | - | -$14.85 M(-11.6%) | -$93.84 M(-5.5%) |
| Dec 2006 | -$99.33 M(+222.6%) | -$16.80 M(-50.2%) | -$99.33 M(-5.8%) |
| Sept 2006 | - | -$33.74 M(+18.6%) | -$105.44 M(+304.0%) |
| June 2006 | - | -$28.44 M(+39.8%) | -$26.10 M(+3.7%) |
| Mar 2006 | - | -$20.35 M(-11.2%) | -$25.16 M(-18.3%) |
| Dec 2005 | -$30.79 M(-69.2%) | -$22.90 M(-150.2%) | -$30.79 M(-16.7%) |
| Sept 2005 | - | $45.60 M(-265.8%) | -$36.95 M(-58.7%) |
| June 2005 | - | -$27.51 M(+5.9%) | -$89.43 M(-11.9%) |
| Mar 2005 | - | -$25.98 M(-10.6%) | -$101.47 M(+1.5%) |
| Dec 2004 | -$99.99 M(-369.3%) | -$29.06 M(+322.0%) | -$99.99 M(+37.8%) |
| Sept 2004 | - | -$6.88 M(-82.6%) | -$72.57 M(+0.7%) |
| June 2004 | - | -$39.55 M(+61.5%) | -$72.06 M(+43.6%) |
| Mar 2004 | - | -$24.49 M(+1391.6%) | -$50.18 M(-235.2%) |
| Dec 2003 | $37.13 M(-146.8%) | -$1.64 M(-74.2%) | $37.13 M(+520.6%) |
| Sept 2003 | - | -$6.38 M(-63.9%) | $5.98 M(-354.9%) |
| June 2003 | - | -$17.67 M(-128.1%) | -$2.35 M(-47.3%) |
| Mar 2003 | - | $62.82 M(-291.6%) | -$4.45 M(-94.4%) |
| Dec 2002 | -$79.36 M(+263.1%) | -$32.79 M(+123.0%) | -$79.36 M(+70.7%) |
| Sept 2002 | - | -$14.71 M(-25.7%) | -$46.49 M(+40.5%) |
| June 2002 | - | -$19.78 M(+63.6%) | -$33.09 M(+28.6%) |
| Mar 2002 | - | -$12.09 M(<-9900.0%) | -$25.73 M(+17.7%) |
| Dec 2001 | -$21.86 M(+17.2%) | $91.00 K(-107.0%) | -$21.86 M(-21.3%) |
| Sept 2001 | - | -$1.30 M(-89.5%) | -$27.77 M(-2.6%) |
| June 2001 | - | -$12.43 M(+51.2%) | -$28.52 M(+14.6%) |
| Mar 2001 | - | -$8.22 M(+41.2%) | -$24.90 M(+33.5%) |
| Dec 2000 | -$18.64 M(+81.0%) | -$5.82 M(+183.3%) | -$18.64 M(+73.9%) |
| Sept 2000 | - | -$2.06 M(-76.7%) | -$10.72 M(-14.0%) |
| June 2000 | - | -$8.80 M(+348.0%) | -$12.47 M(+50.9%) |
| Mar 2000 | - | -$1.97 M(-193.6%) | -$8.27 M(-19.8%) |
| Dec 1999 | -$10.30 M(-3.7%) | $2.10 M(-155.3%) | -$10.30 M(-31.8%) |
| Sept 1999 | - | -$3.80 M(-17.4%) | -$15.10 M(+31.3%) |
| June 1999 | - | -$4.60 M(+15.0%) | -$11.50 M(+27.8%) |
| Mar 1999 | - | -$4.00 M(+48.1%) | -$9.00 M(-15.9%) |
| Dec 1998 | -$10.70 M(-197.3%) | -$2.70 M(+1250.0%) | -$10.70 M(-813.3%) |
| Sept 1998 | - | -$200.00 K(-90.5%) | $1.50 M(-78.6%) |
| June 1998 | - | -$2.10 M(-63.2%) | $7.00 M(+133.3%) |
| Mar 1998 | - | -$5.70 M(-160.0%) | $3.00 M(-72.7%) |
| Dec 1997 | $11.00 M(+64.2%) | $9.50 M(+79.2%) | $11.00 M(-4.3%) |
| Sept 1997 | - | $5.30 M(-186.9%) | $11.50 M(+105.4%) |
| June 1997 | - | -$6.10 M(-365.2%) | $5.60 M(-51.7%) |
| Mar 1997 | - | $2.30 M(-77.0%) | $11.60 M(+73.1%) |
| Dec 1996 | $6.70 M | $10.00 M(-1766.7%) | $6.70 M(-303.0%) |
| Sept 1996 | - | -$600.00 K(+500.0%) | -$3.30 M(+22.2%) |
| June 1996 | - | -$100.00 K(-96.2%) | -$2.70 M(+3.8%) |
| Mar 1996 | - | -$2.60 M | -$2.60 M |
FAQ
- What is Neurocrine Biosciences annual cash flow from operations?
- What is the all time high annual CFO for Neurocrine Biosciences?
- What is Neurocrine Biosciences annual CFO year-on-year change?
- What is Neurocrine Biosciences quarterly cash flow from operations?
- What is the all time high quarterly CFO for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly CFO year-on-year change?
- What is Neurocrine Biosciences TTM cash flow from operations?
- What is the all time high TTM CFO for Neurocrine Biosciences?
- What is Neurocrine Biosciences TTM CFO year-on-year change?
What is Neurocrine Biosciences annual cash flow from operations?
The current annual CFO of NBIX is $389.90 M
What is the all time high annual CFO for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual cash flow from operations is $389.90 M
What is Neurocrine Biosciences annual CFO year-on-year change?
Over the past year, NBIX annual cash flow from operations has changed by +$50.50 M (+14.88%)
What is Neurocrine Biosciences quarterly cash flow from operations?
The current quarterly CFO of NBIX is $158.00 M
What is the all time high quarterly CFO for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly cash flow from operations is $212.00 M
What is Neurocrine Biosciences quarterly CFO year-on-year change?
Over the past year, NBIX quarterly cash flow from operations has changed by -$54.00 M (-25.47%)
What is Neurocrine Biosciences TTM cash flow from operations?
The current TTM CFO of NBIX is $476.40 M
What is the all time high TTM CFO for Neurocrine Biosciences?
Neurocrine Biosciences all-time high TTM cash flow from operations is $645.40 M
What is Neurocrine Biosciences TTM CFO year-on-year change?
Over the past year, NBIX TTM cash flow from operations has changed by +$67.00 M (+16.37%)